Status:

RECRUITING

Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study

Lead Sponsor:

Antonios Likourezos

Conditions:

Urinary Tract Infections

Eligibility:

FEMALE

14-110 years

Brief Summary

The purpose of this study is to determine if a single dose of amikacin (a type of antibiotic) can be used to effectively treat emergency department patients with uncomplicated cystitis (inflammation o...

Detailed Description

he study is a prospective open-label cohort study that seeks to enroll 75 ED patients diagnosed with uncomplicated cystitis. Enrolled patients will be treated with a single dose of amikacin. The prima...

Eligibility Criteria

Inclusion

  • female emergency medicine patients
  • ≥14 years of age
  • uncomplicated urinary tract infection
  • a primary urinary complaint and nitrite-positive urine.

Exclusion

  • pregnancy
  • abnormal genitourinary tract
  • recent urinary tract instrumentation
  • immunosuppression
  • CrCl \< 25 mL/min
  • evidence of pyelonephritis or sepsis
  • any antibiotic treatment within 30 days
  • not available for phone follow-up in 3, 7, and 30 days
  • requires admission to the hospital
  • abnormal mental status.

Key Trial Info

Start Date :

September 21 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT05227937

Start Date

September 21 2022

End Date

December 31 2025

Last Update

September 5 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Maimonides Medical Center

Brooklyn, New York, United States, 11219

Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study | DecenTrialz